Global Immune Checkpoint Inhibitors Market Research Report: Forecast (2025-2030)

Immune Checkpoint Inhibitors Market - By Drug Class (PD- 1 (Opdivo (Nivolumab), Keytruda (Pembrolizumab)), PD- L1 (Tecentriq (Atezolizumab), Bavencio (Avelumab), Imfinzi (Durvalumab), CTLA- 4 (Yervoy... ... b), CTLA- 4 (Yervoy (Ipilimumab)), By Application (Melanoma, Hodgkin Lymphoma, Renal Cell Cancer, Urothelial Cancer, Non-Small Cell Lung Cancer (NSCLC), Others (Head & Neck Cancers, etc.)), By End-User (Hospitals, Clinics, Specialty Cancer Centers) and others Read more

  • Healthcare
  • Jun 2022
  • 198
  • PDF, Excel, PPT

Market Definition

The Immune Checkpoints are the basic part of the immune system. The main function of these checkpoint inhibitors is to intercept the immune checkpoint inhibitors from being robust so that it can easily prevent the healthy cells present in the body. Moreover, the inhibitors engage when proteins on the surface of immune cells known as T cells recognize and tie up to partner proteins on the other cells, like tumor cells. These proteins are also known as ‘Immune Checkpoint Proteins.’ So, when the checkpoint and partner proteins bind together, they send an ‘Off’ signal to the T cells. It helps in preventing the immune system from being destroyed by the cancer.

The checkpoint inhibitors work by releasing a natural brake on the immune system so that the immune cells identify and attack tumors. This therapy is also known as ‘Checkpoint Blockage’ as the molecule acts as a brake on immune cells – the checkpoint – is blocked by the drug.

Market Insights & Analysis: Global Immune Checkpoint Inhibitors Market (2025-30):

The Global Immune Checkpoint Inhibitor Market size was valued at around USD 51.2 billion in 2023 and is projected to grow at a CAGR of 15.6% during the forecast period of 2025-30. The growth of the market has transformed the treatment of cancer by combining the immune system of the body in order to target and destroy cancer cells. The industry of immune checkpoint inhibitors has observed substantial growth due to continuing research, clinical trials, and a rise in the number of approved therapies. Moreover, the commonness of various types of cancers such as breast, lung, cervical, bladder, melanoma, and Hodgkin lymphoma is leading to the adoption of immune checkpoint inhibitor therapies.

Report Coverage Details
  Historical Years   2020-23
  Base Years
  2024
  Forecast Years
  2025-30
  Market Value in 2023   USD 51.2 Billion
  CAGR (2025-30)   15.6%
  Leading Region   North America
  Top Key Players AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bluebird Bio, Inc., Bristol Myers Squibb, CARsgen Therapeutics, Eli Lilly and Company, GlaxoSmithKline PLC, Merck & Co., Inc., Novartis International AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi S.A., Sun Pharmaceutical Industries Ltd., Others
  Key Report Highlights
  • Market Dimensions & Projections
  • Pricing Evaluation,
  • Recent Strategic Moves by Companies,
  • Primary Stakeholders,
  • Analysis of Import and Export Trends,
  • Competitive Landscape Assessment,
  • Emerging Opportunities,
  • Market Trends and Indicators

 

*Boost strategic growth with in-depth market analysis - Get a free sample preview today!

Moreover, the rising awareness among patients regarding the advantages of checkpoint inhibitors such as minimum side effects & targeted therapeutic effects is another significant factor aspect fueling the demand for immune checkpoint inhibitors across the globe. As a result, it is attracting huge funding from multiple biotech companies, pharmaceuticals, universities, and cancer centers in the research and development of more effective immune checkpoint inhibitors, and thriving the overall growth of the industry.

However, the research and development require heavy expenses, also the lack of awareness among people for using these immune checkpoint inhibitors, mainly in developing regions hampers the expansion of the immune checkpoint inhibitors industry across the world.

  1. Introduction
    1. Research Process
    2. Assumption
    3. Market Segmentation
    4. Market Definition
  2. Executive Summary
  3. Global Immune Checkpoint Inhibitors Market Trends & Insights
  4. Global Immune Checkpoint Inhibitors Market Regulation & Policy, By Country
  5. Global Immune Checkpoint Inhibitors Market Dynamics
    1. Growth Drivers
    2. Challenges
    3. Impact Analysis
  6. Global Immune Checkpoint Inhibitors Market Hotspot and Opportunities
  7. Global Immune Checkpoint Inhibitors Market Outlook, 2020- 2030
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Drug Class
        1. PD- 1
          1. Opdivo (Nivolumab)
          2. Keytruda (Pembrolizumab)
        2. PD- L1
          1. Tecentriq (Atezolizumab)
          2. Bavencio (Avelumab)
          3. Imfinzi (Durvalumab)
        3. CTLA- 4
          1. Yervoy (Ipilimumab)
      2. By Application
        1. Melanoma
        2. Hodgkin Lymphoma
        3. Renal Cell Cancer
        4. Urothelial Cancer
        5. Non-Small Cell Lung Cancer (NSCLC)
        6. Others (Head & Neck Cancers, etc.)
      3. By End-User
        1. Hospitals
        2. Clinics
        3. Specialty Cancer Centers
      4. By Region
        1. North America
        2. South America
        3. Europe
        4. Middle East & Africa
        5. Asia-Pacific
      5. By Company
        1. Competition Characteristics
        2. Revenue Shares
        3. Competitor Placement in MarkNtel Advisor’s Quadrant
  8. North America Immune Checkpoint Inhibitors Outlook, 2020- 2030
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Drug Class
      2. By Application
      3. By End-User
      4. By Country
        1. The US
        2. Canada
        3. Mexico
  9. South America Immune Checkpoint Inhibitors Outlook, 2020- 2030
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Drug Class
      2. By Application
      3. By End-User
      4. By Country
        1. Brazil
        2. Rest of Latin America
  10. Europe Immune Checkpoint Inhibitors Outlook, 2020- 2030
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Drug Class
      2. By Application
      3. By End-User
      4. By Country
        1. The UK
        2. Germany
        3. France
        4. Italy
        5. Spain
        6. Rest of Europe
  11. Middle East & Africa Immune Checkpoint Inhibitors Outlook, 2020- 2030
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Drug Class
      2. By Application
      3. By End-User
      4. By Country
        1. South Africa
        2. GCC
        3. Rest of Middle East & Africa
  12. Asia-Pacific Immune Checkpoint Inhibitors Outlook, 2020- 2030
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Drug Class
      2. By Application
      3. By End-User
      4. By Country
        1. China
        2. Japan
        3. India
        4. Australia
        5. South East Asia
        6. Rest of Asia Pacific
  13. Global Immune Checkpoint Inhibitors Market Key Strategic Imperatives for Success and Growth
  14. Competitive Outlook
    1. Competition Matrix
      1. By Application Portfolio
      2. Brand Specialization
      3. Target Markets
      4. Target by Applications
      5. Research & Development
      6. Strategic Alliances
      7. Strategic Initiatives
    2. Company Profiles (Business Description, By Application Segments, Business Segments, Financials, Strategic Alliances/ Partnerships, Future Plans)
      1. AbbVie Inc.
      2. Amgen Inc.
      3. AstraZeneca PLC
      4. Bluebird Bio, Inc.
      5. Bristol Myers Squibb
      6. CARsgen Therapeutics
      7. Eli Lilly and Company
      8. GlaxoSmithKline PLC
      9. Merck & Co., Inc.
      10. Novartis International AG
      11. Pfizer Inc.
      12. Regeneron Pharmaceuticals Inc.
      13. Sanofi S.A.
      14. Sun Pharmaceutical Industries Ltd.
      15. Others
  15. Disclaimer


MarkNtel Advisors follows a robust and iterative research methodology designed to ensure maximum accuracy and minimize deviation in market estimates and forecasts. Our approach combines both bottom-up and top-down techniques to effectively segment and quantify various aspects of the market. A consistent feature across all our research reports is data triangulation, which examines the market from three distinct perspectives to validate findings. Key components of our research process include:

1. Scope & Research Design At the outset, MarkNtel Advisors define the research objectives and formulate pertinent questions. This phase involves determining the type of research—qualitative or quantitative—and designing a methodology that outlines data collection methods, target demographics, and analytical tools. They also establish timelines and budgets to ensure the research aligns with client goals.

2. Sample Selection and Data Collection In this stage, the firm identifies the target audience and determines the appropriate sample size to ensure representativeness. They employ various sampling methods, such as random or stratified sampling, based on the research objectives. Data collection is carried out using tools like surveys, interviews, and observations, ensuring the gathered data is reliable and relevant.

3. Data Analysis and Validation Once data is collected, MarkNtel Advisors undertake a rigorous analysis process. This includes cleaning the data to remove inconsistencies, employing statistical software for quantitative analysis, and thematic analysis for qualitative data. Validation steps are taken to ensure the accuracy and reliability of the findings, minimizing biases and errors.

Data Trangulation

4. Data Forecast and FinalizationThe final phase involves forecasting future market trends based on the analyzed data. MarkNtel Advisors utilize predictive modeling and time series analysis to anticipate market behaviors. The insights are then compiled into comprehensive reports, featuring visual aids like charts and graphs, and include strategic recommendations to inform client decision-making

We’d love to understand what matters most to you.

Your data is 100% confidential & secure

By submitting, you agree to our Terms and Privacy Policy .